Table 3

Adjusted association of individual–level and country–level characteristics with use of e-cigarettes and cigarettes in WHO European region countries, ESPAD 2019

Current use (ie, past 30 days) (vs none)Ever use (vs none)
E-cigarettes
OR (95% CI)
Cigarettes
OR (95% CI)
Dual use
OR (95% CI)
E-cigarettes
OR (95% CI)
Cigarettes
OR (95% CI)
Dual use
OR (95% CI)
Individual level
 Girls (vs boys)0.53*** (0.45 to 0.63)1.17** (1.05 to 1.30)0.72*** (0.64 to 0.82)0.50*** (0.43 to 0.60)1.23*** (1.10 to 1.37)0.67*** (0.60 to 0.75)
 High education in the family (vs primary/secondary)0.86*** (0.79 to 0.94)0.81*** (0.76 to 0.87)0.75*** (0.67 to 0.83)0.90* (0.82 to 0.98)0.85*** (0.79 to 0.92)0.81*** (0.73 to 0.90)
 Perceived family’s financial well-being (continuous, from lowest to highest)1.05* (1.01 to 1.08)0.99 (0.97 to 1.01)1.05* (1.00 to 1.10)1.03 (1.00 to 1.07)0.96** (0.94 to 0.99)1.02 (0.99 to 1.05)
 Perceived difficulty of getting cigarettes (continuous, from lowest to highest)0.91*** (0.88 to 0.95)0.87*** (0.82 to 0.91)0.80*** (0.76 to 0.85)0.94*** (0.92 to 0.96)0.91*** (0.89 to 0.93)0.83*** (0.79 to 0.86)
Country level
 Score on e–cigarette regulations (continuous)0.78* (0.65 to 0.94)0.96 (0.79 to 1.15)0.80* (0.67 to 0.95)0.86 (0.74 to 1.01)0.98 (0.81 to 1.18)0.86 (0.72 to 1.03)
 MPOWER score 2014–2018 increase (vs no/decrease)0.66 (0.40 to 1.06)2.02 (0.83 to 4.93)0.97 (0.55 to 1.73)0.79 (0.51 to 1.23)2.34 (0.88 to 6.22)1.18 (0.62 to 2.26)
 Middle-income country group (vs high)0.33*** (0.19 to 0.58)1.51 (0.80 to 2.84)0.46** (0.27 to 0.76)0.40** (0.21 to 0.75)2.42** (1.27 to 4.61)0.55* (0.31 to 0.96)
  • All listed variables were included as fixed effects in each of the six weighted multilevel models with a country random intercept. Starting from the multivariable model on current e-cigarette use (from left to right), the unweighted numbers of observations were 64 182; 69 459; 64 480; 67 085; 49 096; and 60 578 from 32 countries.

  • ***P<0.001; **p<0.01; *p<05.

  • ESPAD, European School Survey Project on Alcohol and Other Drugs.